Demand and volumepositive · 4 filings
“Inventories used $86.3 million of cash due to increased quantities associated with the Acquisition in response to anticipated tariffs and forecasted future demand.”10-K · Aug 26, 2026 ↗
Phibro Animal Health Corporation
PAHC
Market read
Phibro Animal Health Corporation's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
Company-2.6% todayVolume comparison unavailable
Market group0 of 15 activeMixed Risk Exposure · unavailable
Disclosed network0 of 1 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- Performance Products reported a 12% decline in nine-month net sales due to lower demand for ingredients used in personal care products.
- Interest expense rose $8.3M (32%) for the nine months, attributed to expiration of a favorable interest rate swap on $300M notional and higher term loan balances.
Invalidation: The isolated read changes if PAHC's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- Performance Products reported a 12% decline in nine-month net sales due to lower demand for ingredients used in personal care products.
- Interest expense rose $8.3M (32%) for the nine months, attributed to expiration of a favorable interest rate swap on $300M notional and higher term loan balances.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations328
Usable filing statements117
Verified relationships6
Evidence supporting the case
- Latest annual revenue changed +17.1% year over year.
- Operating margin changed +4.3 percentage points in the latest annual period.
- Net margin changed +2.8 percentage points in the latest annual period.
- Demand and volume has repeated favorable evidence across 4 filings.
- Credit and interest rates has repeated favorable evidence across 3 filings.
Evidence challenging the case
No qualifying adverse evidence was identified; that is not proof there is no downside.
Questions before a position
- P/E is 25% above the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 58% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 11, 2026
35.636m-27.3%12m-13.5%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2022-06-30$942.3M+13.1%$1.21+0.0%
2023-06-30$977.9M+3.8%$0.81+0.0%
2024-06-30$1.0B+4.1%$0.06+0.0%
2025-06-30$1.3B+27.4%$1.19+0.4%
2026-06-30$1.5B+17.1%$2.43+0.7%
What management says matters
Persistent and emerging business drivers
Credit and interest ratespositive · 3 filings
“Interest expense, net increased $8.3 million due to the expiration of an interest rate swap agreement and higher debt levels associated with the refinancing of the Company’s debt.”10-Q · May 6, 2026 ↗
Foreign exchangemixed · 1 filings
“Animal Health gross profit, excluding the purchase accounting item discussed above, increased $67.2 million, driven by higher sales volume, favorable product mix, and increases in average selling prices, partially offset by higher input and distribution costs…”10-Q · Feb 4, 2026 ↗
Tariffs and trade policypositive · 1 filings
“Inventories used $86.3 million of cash due to increased quantities associated with the Acquisition in response to anticipated tariffs and forecasted future demand.”10-K · Aug 26, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 1.0× · EV/sales 0.9×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
35.63-2.6% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for PAHC. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for PAHC. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind PAHC
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ZTSZoetis Inc.investeeFeb 4, 2026 ▾
“Acquisition In April 2024, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’s medicated feed additive (“MFA”) portfolio, certain water-soluble products and…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PAHC is currently a Leader in the organic co-movement group Mixed Risk Exposure. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for PAHC; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.